Endologix Inc
 (ELGX)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Nov. 27, 2015, 2:39 PM
    • Top gainers, as of 2.15 p.m.: HSC +49.7%. WPC +46.3%. ELGX +19.2%. OA +12.4%. HOS +12.3%.
    • Top losers, as of 2.15p.m.: HMSY -27.4%. EXPR -20.7%. PE -12.2%. NKTR -11.1%. SAP -10.4%.
    | Nov. 27, 2015, 2:39 PM | 21 Comments
  • Oct. 27, 2015, 12:42 PM
    | Oct. 27, 2015, 12:42 PM
  • Oct. 26, 2015, 4:27 PM
    • Endologix (NASDAQ:ELGX) acquires TriVascular Technologies (NASDAQ:TRIV) in a cash-and-stock deal valued at $9.10 per TRIV share or $211M. The stock portion of the deal will be equal to 19.999% of ELGX's outstanding shares while the cash portion will be determined at the closing date and will be based on the value of TRIV options, restricted stock units, warrants, and, if applicable, the conversion of TRIV convertible debt. When the transaction closes in January, ELGX shareholders will own ~84% of the shares of the combined company.
    • Endologix CEO John McDermott says, "This merger enhances the near and long-term growth potential of our business by bringing together two of the most innovative companies in the field of endovascular abdominal aortic aneurysm treatment."
    • TRIV is up 54% after hours on light volume.
    | Oct. 26, 2015, 4:27 PM | 1 Comment
  • Sep. 29, 2014, 12:49 PM
    | Sep. 29, 2014, 12:49 PM
  • Feb. 28, 2014, 12:59 PM
    • Endologix (ELGX -23.9%) shares plummet after the medical device maker reports mixed Q4 results and forecasts FY 2014 revenues below analyst consensus due to slow growth in U.S. device sales.
    • ELGX sees FY 2014 GAAP EPS loss of $0.44-$0.31 vs. analyst consensus estimate of flat earnings, and revenues of $146M-$152M vs. $161M consensus.
    • Oppenheimer downgrades shares to Perform from Outperform and lowers its price target to $16 from $20 on ELGX's disappointing 6%-10% 2014 U.S. growth forecast following 18% growth in 2013; the firm still sees Nellix as a long-term growth driver, but there's little to offset near-term U.S. uncertainty with no Nellix data read-outs expected this year and EU constraints not expected to be alleviated until Q4.
    | Feb. 28, 2014, 12:59 PM
  • Feb. 28, 2014, 12:46 PM
    | Feb. 28, 2014, 12:46 PM | 5 Comments
  • Feb. 28, 2014, 9:14 AM
    | Feb. 28, 2014, 9:14 AM
  • Feb. 27, 2014, 5:38 PM
    • Top gainers, as of 5:15 p.m.: OVTI +14.3%. IG +11.7%. AL +11.3%. YOKU +6.6%. MELI +6.4%.
    • Top losers, as of 5:15 p.m.: ELGX -21.1%. YUME -16.8%. DECK -11.7%. KBR -7.6%. CGEN -7.2%.
    | Feb. 27, 2014, 5:38 PM
  • May 1, 2013, 9:10 AM
    Premarket gainers: IQNT +34%. MSPD +31%. TRLA +14%. FIRE +12%. JRCC +11%. CAAS +8%. DWA +9%. GDOT +8%. CAVM +8%. NAVB +5%.
    Losers: HIMX -9%. ELGX -8%. SWI -8%.
    | May 1, 2013, 9:10 AM
  • Jan. 28, 2013, 12:37 PM

    Endologix (ELGX +2.3%) presents data from its clinical trial of a totally percutaneous approach to endovascular abdominal aortic aneurysm repair, says the study demonstrated that the approach is non-inferior to surgical endovascular repair, and also has significantly reduced procedure times and time to hemostasis. The study also demonstrated positive trends toward lower blood loss, less need for pain medication, and shorter lengths of stay.

    | Jan. 28, 2013, 12:37 PM
  • Dec. 31, 2012, 2:59 PM

    Endologix (ELGX +1%) says its distribution partner in Japan, Cosmotec, has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the IntuiTrak Delivery System. The IntuiTrak System delivers ELGX's Powerlink anatomical fixation stent graft for the repair of abdominal aortic aneurysms.

    | Dec. 31, 2012, 2:59 PM
  • Jun. 12, 2012, 1:27 PM

    Endologix (ELGX +1.8%) pipeline looks impressive, says Oppenheimer. After meeting with management, the firm says ELGX's growth story remains intact and that abdominal aortic aneurysm market volumes and pricing remain solid. The firm thinks the Street is still underestimating the value of the company's Nelix treatment and reiterates a Buy on the stock.

    | Jun. 12, 2012, 1:27 PM
  • Feb. 2, 2012, 9:00 AM

    Premarket gainers: GMCR +21%. CEDC +21%. MTSN +15%. OMEX +10%. GPS +8%. CNQR +6%. EA +6%. CDNS +6%. QCOM +5%. ELGX +5%. GFA +5%. AUO +4%. KSS +4%. ZNGA +4%. IRE +4%. CMI +3%. K +3%. CPST +3%. JDSU +3%. MA +3%. RENN +3%.
    Losers: SD -13%. ANF -12%. ANN -10%. NG -9%. BSX -6%. CI -6%. RCL -6%. UN -5%. MPW +4%. VIA -4%. UL -4%. CHKM -4%. SNE -4%. PCX -4%. PHM -3%. DOW -3%. ANZ -3%. CUK -3%. CCL -3%. NBG -3%.

    | Feb. 2, 2012, 9:00 AM
Company Description
Endologix Inc develops, manufactures, markets & sells medical devices for the treatment of aortic disorders. Its EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System.